FDA ENTERING 1997 WITH ALLIES FOR GENERIC AND OTC USER FEE DISCUSSIONS; GENERIC COMPANIES BEGINNING TO FORMULATE STRATEGY FOR WAXMAN/HATCH REVISIONS
Executive Summary
FDA will enter the 1997 Prescription Drug User Fee Act reauthorization process with some support from industry for expansion of user fees to generic and OTC drugs.